ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Capital expenditures 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$886,000FY2024 · since FY2016: $11.5M → $886,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $886,000 | -81.1% |
| FY2023 | $4.7M | -84.1% |
| FY2022 | $29.5M | +244.0% |
| FY2021 | $8.6M | +266.3% |
| FY2020 | $2.3M | +47.0% |
| FY2019 | $1.6M | -59.3% |
| FY2018 | $3.9M | -84.1% |
| FY2017 | $24.6M | +114.2% |
| FY2016 | $11.5M | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Operating cash flowADAPY Free cash flowADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →